U.S. License Holder:
Astellas
Date of License:
December-18-2019
Last Update:
Nov-30-2023
FDA-Approved Indications
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated:
As a single agent for the treatment of adult patients with locally advanced or metastatic urothelial cancer who: Have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy;
in combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy.
